Regulations for international non-proprietary name prescribing and substitution, relevant for cross-border ePrescribing and eDispensation services in the European Union
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.International Non-Proprietary Name (INN) prescribing and substitution rules vary across EU nations. Harmonizing these regulations, potentially through Identification of Medicinal Products (IDMP) standards, is crucial for rational prescribing and cross-border healthcare.
Area Of Science
- Health Policy
- Pharmaceutical Sciences
- Health Informatics
Background
- Rational prescribing and cost containment policies advocate for International Non-Proprietary Name (INN) prescribing and substitution.
- Existing national regulations in European Union (EU) member states vary significantly regarding INN prescribing and drug substitution.
- The development of nation-specific ePrescribing and eDispensation systems requires understanding these diverse regulatory landscapes.
Purpose Of The Study
- To delineate the national regulations governing INN prescribing and drug substitution across EU countries.
- To explore the potential for harmonizing these rules within the framework of Identification of Medicinal Products (IDMP) standards for the European Health Data Space.
- To inform the development of cross-border ePrescribing and eDispensing services.
Main Methods
- A survey was distributed to policy makers from national competent authorities within the UNICOM initiative.
- Data collection focused on national regulations concerning INN prescribing and drug substitution.
- Fourteen EU countries participated, providing insights into their specific regulatory tools and practices.
Main Results
- INN prescribing is mandatory in Greece, Portugal, and Estonia; allowed in Germany, Belgium, Norway, Spain, the Netherlands, and Italy.
- Substitution based on substance and dose form is mandatory in Finland and Sweden; allowed in Ireland.
- Austria and Croatia permit only brand substitution, highlighting significant regulatory divergence.
Conclusions
- Harmonization of national INN prescribing and substitution rules, including exemptions and physician veto options, is necessary.
- Implementation of Identification of Medicinal Products (IDMP) standards can facilitate this harmonization.
- Standardized regulations will significantly impact pharmaceutical research, drug shortage management, and clinical care across the EU.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.